May 3, 2018
Authored and Edited by Ashley M. Winkler; Kara A. Specht; Elizabeth D. Ferrill
In Gilead Sciences, Inc. v. Merck & Co., the Federal Circuit affirmed the district court’s decision finding that Merck’s pre-litigation business misconduct and litigation misconduct barred it from asserting two patents against Gilead under the unclean hands doctrine. The district court decision vacated a $200 million jury award for infringement of Merck’s patents.
The district court found that Dr. Durette, an inventor and patent agent for Merck, had participated in a conference call with Gildead’s predecessor-in-interest related to the sofosbuvir compound. In violation of a confidentiality agreement, Dr. Durette then used information from that call to narrow the claims of a pending application to target a specific group of compounds, including sofosbuvir. Ultimately this application resulted in two patents, and Merck sued Gilead for infringement. Although Dr. Durette repeatedly testified at his deposition that he could not recall whether he had participated in the conference call, at trial, Dr. Durette admitted that he had known about the call.
Judge Taranto noted that the doctrine of unclean hands should not be invoked lightly but found that the evidence in this case did not support overturning the district court decision. He stated that the “findings establish serious misconduct, violating clear standards of probity in the circumstances.”
Copyright © 2018 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP.
DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. One of our lawyers will be happy to discuss the possibility of representation with you. Additional disclaimer information.
Hybrid Conference
2024 California Intellectual Property Law Institute
October 21-22,2024
San Francisco
Hybrid Conference
2024 New York Intellectual Property Law Institute
September 30 - October 1, 2024
New York
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.